Plain-English translation of NCT06134362 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for people who have been participating in earlier trials of cabotegravir (), a long-acting injectable medication designed to prevent HIV infection. Researchers want to continue monitoring your health, check that the medication is working to protect you from HIV, and watch for any side effects over the long term.
Earlier studies showed this medication was effective at preventing HIV in people at higher risk. This trial exists to make sure the medication continues to be safe and protective over many months and years of regular use.
You will continue to receive the same injectable medication every 8 weeks as an injection into your buttock muscle, just as you have been doing in the previous study. The research team will monitor you through regular visits to check for HIV infection, watch for any side effects or injection-site reactions, and track your overall health. The study will follow you for an extended period to understand the long-term safety and effectiveness of this prevention approach.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
Argentina
Botswana
Brazil